MY140975A - Gene construct encoding a heterologous prodrug-activating enzyme and a cell targeting moiety - Google Patents
Gene construct encoding a heterologous prodrug-activating enzyme and a cell targeting moietyInfo
- Publication number
- MY140975A MY140975A MYPI98002086A MYPI9802086A MY140975A MY 140975 A MY140975 A MY 140975A MY PI98002086 A MYPI98002086 A MY PI98002086A MY PI9802086 A MYPI9802086 A MY PI9802086A MY 140975 A MY140975 A MY 140975A
- Authority
- MY
- Malaysia
- Prior art keywords
- targeting moiety
- gene construct
- cell targeting
- construct encoding
- cell
- Prior art date
Links
- 230000008685 targeting Effects 0.000 title abstract 4
- 108090000790 Enzymes Proteins 0.000 title abstract 3
- 102000004190 Enzymes Human genes 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 210000004027 cell Anatomy 0.000 abstract 5
- 101710160107 Outer membrane protein A Proteins 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000004807 localization Effects 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/802—Virus-based particle
- Y10S977/803—Containing biological material in its interior
- Y10S977/804—Containing nucleic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nanotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Crystallography & Structural Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9709421.3A GB9709421D0 (en) | 1997-05-10 | 1997-05-10 | Chemical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY140975A true MY140975A (en) | 2010-02-12 |
Family
ID=10812048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI98002086A MY140975A (en) | 1997-05-10 | 1998-05-08 | Gene construct encoding a heterologous prodrug-activating enzyme and a cell targeting moiety |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US6339070B1 (enExample) |
| EP (1) | EP0979292B1 (enExample) |
| JP (1) | JP2001526539A (enExample) |
| KR (1) | KR100508136B1 (enExample) |
| CN (1) | CN1268743C (enExample) |
| AT (1) | ATE412755T1 (enExample) |
| AU (1) | AU734915B2 (enExample) |
| BR (1) | BR9808769A (enExample) |
| CA (1) | CA2286875A1 (enExample) |
| DE (1) | DE69840165D1 (enExample) |
| ES (1) | ES2314990T3 (enExample) |
| GB (2) | GB9709421D0 (enExample) |
| HU (1) | HUP0001931A3 (enExample) |
| IL (1) | IL132348A0 (enExample) |
| MY (1) | MY140975A (enExample) |
| NO (1) | NO995475L (enExample) |
| NZ (1) | NZ500014A (enExample) |
| PL (1) | PL337007A1 (enExample) |
| RU (1) | RU2218404C2 (enExample) |
| SK (1) | SK153599A3 (enExample) |
| TR (1) | TR199902731T2 (enExample) |
| WO (1) | WO1998051787A2 (enExample) |
| ZA (1) | ZA983931B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9910077D0 (en) | 1999-05-01 | 1999-06-30 | Univ Manchester | Chemical compounds |
| DE19946142A1 (de) | 1999-09-27 | 2001-03-29 | Bundesrepublik Deutschland Let | Gentransfer in humane Lymphocyten mittels retroviraler scFv-Zelltargeting Vektoren |
| GB0001653D0 (en) * | 2000-01-26 | 2000-03-15 | Astrazeneca Uk Ltd | Chemical compound |
| GB0102239D0 (en) | 2001-01-29 | 2001-03-14 | Cancer Res Ventures Ltd | Methods of chemical synthisis |
| WO2002094318A1 (en) * | 2001-05-18 | 2002-11-28 | University Of Southern California | Vector for targeted delivery to cells |
| US7244592B2 (en) | 2002-03-07 | 2007-07-17 | Dyax Corp. | Ligand screening and discovery |
| AU2003239197A1 (en) * | 2002-06-07 | 2003-12-22 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of | Novel stable anti-cd22 antibodies |
| US20050107320A1 (en) * | 2003-01-30 | 2005-05-19 | Matthew During | Methods and compositions for use in interventional pharmacogenomics |
| PT2829283T (pt) | 2003-04-30 | 2017-09-08 | Univ Zuerich | Método para tratamento do cancro utilizando uma imunotoxina |
| WO2005058236A2 (en) * | 2003-12-12 | 2005-06-30 | Genencor International, Inc. | Cab molecules |
| JP4823894B2 (ja) | 2004-04-09 | 2011-11-24 | 中外製薬株式会社 | 新規水溶性プロドラッグ |
| US20060105941A1 (en) * | 2004-11-12 | 2006-05-18 | Allergan, Inc. | Mixed antibiotic codrugs |
| TW200744603A (en) | 2005-08-22 | 2007-12-16 | Chugai Pharmaceutical Co Ltd | Novel anticancer concomitant drug |
| CA2633756C (en) * | 2005-12-21 | 2015-11-24 | Micromet Ag | Pharmaceutical antibody compositions with resistance to soluble cea |
| US8263744B2 (en) * | 2007-04-19 | 2012-09-11 | Viventia Biotechnologies Inc. | Binding proteins that bind to EpCAM linked to an effector molecule |
| CA2700815A1 (en) * | 2007-09-27 | 2009-04-02 | Viventia Biotech Inc. | Optimized nucleic acid sequences for the expression of vb4-845 |
| WO2010019257A2 (en) | 2008-08-13 | 2010-02-18 | The Johns Hopkins University | Prodrug activation in cancer cells using molecular switches |
| WO2010085665A2 (en) | 2009-01-23 | 2010-07-29 | Cedars-Sinai Medical Center | Targeted delivery system |
| CN104203982B (zh) * | 2011-10-28 | 2018-08-31 | 特瓦制药澳大利亚私人有限公司 | 多肽构建体及其用途 |
| CN104619839A (zh) | 2012-08-03 | 2015-05-13 | 西塞医疗中心 | 药物递送蛋白质的增强运输的突变体的分离 |
| US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
| CN105764925A (zh) | 2013-10-02 | 2016-07-13 | 维文蒂亚生物公司 | 抗EpCAM抗体和使用方法 |
| UA119352C2 (uk) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
| EA037749B1 (ru) | 2014-10-29 | 2021-05-18 | Тева Фармасьютикалз Острэйлиа Пти Лтд | ВАРИАНТЫ ИНТЕРФЕРОНА 2b |
| WO2016145349A1 (en) | 2015-03-12 | 2016-09-15 | Viventia Bio Inc. | Methods of treatment for epcam positive bladder cancer |
| CA2979400A1 (en) | 2015-03-12 | 2016-09-15 | Viventia Bio Inc. | Dosing strategies for targeting epcam positive bladder cancer |
| MX2022011806A (es) | 2020-03-24 | 2023-01-11 | Generation Bio Co | Vectores de adn no virales y usos de estos para expresar agentes terapéuticos contra gaucher. |
| JP2023520764A (ja) | 2020-03-24 | 2023-05-19 | ジェネレーション バイオ カンパニー | 第ｉｘ因子治療薬を発現するための非ウイルス性ｄｎａベクター及びその使用 |
| WO2024040222A1 (en) | 2022-08-19 | 2024-02-22 | Generation Bio Co. | Cleavable closed-ended dna (cedna) and methods of use thereof |
| CN119454938B (zh) * | 2024-11-15 | 2025-07-25 | 广州骐骥生物科技有限公司 | 一种枸橼酸透析浓缩液及其制备方法 |
| CN119564851B (zh) * | 2024-12-05 | 2025-08-22 | 广州骐骥生物科技有限公司 | 一种冰醋酸透析浓缩液及其制备方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5632990A (en) * | 1988-04-22 | 1997-05-27 | Cancer Research Campaign Tech. Ltd. | Treatment for tumors comprising conjugated antibody A5B7 and a prodrug |
| GB8809616D0 (en) * | 1988-04-22 | 1988-05-25 | Cancer Res Campaign Tech | Further improvements relating to drug delivery systems |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| EP1645635A3 (en) | 1989-08-18 | 2010-07-07 | Oxford Biomedica (UK) Limited | Replication defective recombinant retroviruses expressing a palliative |
| US6337209B1 (en) | 1992-02-26 | 2002-01-08 | Glaxo Wellcome Inc. | Molecular constructs containing a carcinoembryonic antigen regulatory sequence |
| GB8919607D0 (en) | 1989-08-30 | 1989-10-11 | Wellcome Found | Novel entities for cancer therapy |
| DE4106389A1 (de) * | 1991-02-28 | 1992-09-03 | Behringwerke Ag | Fusionsproteine zur prodrug-aktivierung, ihre herstellung und verwendung |
| US5314995A (en) * | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| GB9014932D0 (en) * | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| GB2276169A (en) * | 1990-07-05 | 1994-09-21 | Celltech Ltd | Antibodies specific for carcinoembryonic antigen |
| DE4110409C2 (de) | 1991-03-29 | 1999-05-27 | Boehringer Ingelheim Int | Neue Protein-Polykation-Konjugate |
| WO1993019163A1 (en) | 1992-03-18 | 1993-09-30 | Yeda Research And Development Co, Ltd. | Chimeric receptor genes and cells transformed therewith |
| GB9314960D0 (en) * | 1992-07-23 | 1993-09-01 | Zeneca Ltd | Chemical compounds |
| US5723287A (en) | 1992-09-22 | 1998-03-03 | Medical Research Council | Recombinant viruses displaying a nonviral polypeptide on their external surface |
| GB9223084D0 (en) | 1992-11-04 | 1992-12-16 | Imp Cancer Res Tech | Compounds to target cells |
| US5464758A (en) * | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
| GB9323008D0 (en) | 1993-11-05 | 1994-01-05 | Connors Thomas | Improvements relating to cancer therapy |
| GB9324807D0 (en) * | 1993-12-03 | 1994-01-19 | Cancer Res Campaign Tech | Tumour antibody |
| GB9415167D0 (en) | 1994-07-27 | 1994-09-14 | Springer Caroline J | Improvements relating to cancer therapy |
| GB9423367D0 (en) | 1994-11-18 | 1995-01-11 | Wellcome Found | Enzyme prodrug therapy |
| BR9510490B1 (pt) * | 1994-12-23 | 2010-10-05 | composição farmacêutica combinada de dois componentes estruturada para uso em um hospedeiro. | |
| CA2227040A1 (en) * | 1995-08-16 | 1997-03-06 | Zeneca Limited | Chemical compounds |
| GB9523703D0 (en) | 1995-11-20 | 1996-01-24 | Wellcome Found | Enzyme prodrug thearapy |
| GB9601640D0 (en) | 1996-01-26 | 1996-03-27 | Cancer Res Campaign Tech | Ligand directed enzyme prodrug therapy |
| ES2279539T3 (es) * | 1996-05-04 | 2007-08-16 | Astrazeneca Ab | Anticuerpo monoclonal anti-cea, conjugados que comprenden dicho anticuerpo, y su uso terapeutico en un sistema adept. |
| AU747602B2 (en) | 1997-06-04 | 2002-05-16 | Oxford Biomedica (Uk) Limited | Vector |
-
1997
- 1997-05-10 GB GBGB9709421.3A patent/GB9709421D0/en active Pending
-
1998
- 1998-05-05 NZ NZ500014A patent/NZ500014A/en unknown
- 1998-05-05 AU AU72254/98A patent/AU734915B2/en not_active Ceased
- 1998-05-05 TR TR1999/02731T patent/TR199902731T2/xx unknown
- 1998-05-05 HU HU0001931A patent/HUP0001931A3/hu not_active Application Discontinuation
- 1998-05-05 KR KR10-1999-7010394A patent/KR100508136B1/ko not_active Expired - Fee Related
- 1998-05-05 AT AT98919380T patent/ATE412755T1/de not_active IP Right Cessation
- 1998-05-05 DE DE69840165T patent/DE69840165D1/de not_active Expired - Fee Related
- 1998-05-05 WO PCT/GB1998/001294 patent/WO1998051787A2/en not_active Ceased
- 1998-05-05 EP EP98919380A patent/EP0979292B1/en not_active Expired - Lifetime
- 1998-05-05 US US09/423,439 patent/US6339070B1/en not_active Expired - Fee Related
- 1998-05-05 ES ES98919380T patent/ES2314990T3/es not_active Expired - Lifetime
- 1998-05-05 SK SK1535-99A patent/SK153599A3/sk unknown
- 1998-05-05 RU RU99126647/13A patent/RU2218404C2/ru active
- 1998-05-05 JP JP54889298A patent/JP2001526539A/ja not_active Ceased
- 1998-05-05 CN CNB988049295A patent/CN1268743C/zh not_active Expired - Fee Related
- 1998-05-05 PL PL98337007A patent/PL337007A1/xx unknown
- 1998-05-05 IL IL13234898A patent/IL132348A0/xx unknown
- 1998-05-05 CA CA002286875A patent/CA2286875A1/en not_active Abandoned
- 1998-05-05 BR BR9808769-0A patent/BR9808769A/pt not_active IP Right Cessation
- 1998-05-05 GB GB9922815A patent/GB2338484B/en not_active Expired - Fee Related
- 1998-05-08 MY MYPI98002086A patent/MY140975A/en unknown
- 1998-05-08 ZA ZA983931A patent/ZA983931B/xx unknown
-
1999
- 1999-11-09 NO NO995475A patent/NO995475L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO1998051787A3 (en) | 1999-04-01 |
| JP2001526539A (ja) | 2001-12-18 |
| TR199902731T2 (xx) | 2000-06-21 |
| ATE412755T1 (de) | 2008-11-15 |
| HUP0001931A3 (en) | 2003-10-28 |
| IL132348A0 (en) | 2001-03-19 |
| KR100508136B1 (ko) | 2005-08-10 |
| BR9808769A (pt) | 2000-08-01 |
| WO1998051787A2 (en) | 1998-11-19 |
| ES2314990T3 (es) | 2009-03-16 |
| CN1268743C (zh) | 2006-08-09 |
| GB2338484B (en) | 2001-11-07 |
| CA2286875A1 (en) | 1998-11-19 |
| GB9922815D0 (en) | 1999-11-24 |
| US6339070B1 (en) | 2002-01-15 |
| AU734915B2 (en) | 2001-06-28 |
| GB9709421D0 (en) | 1997-07-02 |
| PL337007A1 (en) | 2000-07-31 |
| EP0979292B1 (en) | 2008-10-29 |
| GB2338484A (en) | 1999-12-22 |
| NZ500014A (en) | 2001-08-31 |
| AU7225498A (en) | 1998-12-08 |
| HUP0001931A2 (hu) | 2000-09-28 |
| SK153599A3 (en) | 2000-06-12 |
| NO995475D0 (no) | 1999-11-09 |
| DE69840165D1 (de) | 2008-12-11 |
| KR20010012441A (ko) | 2001-02-15 |
| ZA983931B (en) | 1998-11-10 |
| CN1255163A (zh) | 2000-05-31 |
| RU2218404C2 (ru) | 2003-12-10 |
| EP0979292A2 (en) | 2000-02-16 |
| NO995475L (no) | 2000-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY140975A (en) | Gene construct encoding a heterologous prodrug-activating enzyme and a cell targeting moiety | |
| AU5308698A (en) | Design principle for constructing expression constructs for gene therapy | |
| EP2216407A3 (en) | Therapeutic Compositions | |
| AU4981101A (en) | Subtilisin variants | |
| EP0919622A3 (en) | Surface expression of enzyme in gene directed prodrug therapy | |
| WO2002016583A3 (en) | Constructs and their use in metabolic pathway engineering | |
| IL148512A0 (en) | Methods for making recombinant proteins using apoptosis inhibitors | |
| AUPQ014699A0 (en) | Amplification of folate-mediated targeting to tumor cells using nanoparticles | |
| WO2002006457A3 (en) | Novel lipase genes | |
| AU5001496A (en) | Introduction of dna into bacillus strains by conjugation | |
| AU2001278734A1 (en) | Method of extensive culture of antigen-specific cytotoxic t cells | |
| AU3644299A (en) | A method for the targeting of proteins produced by (yersinia) into the cytosol of eukaryotic cells | |
| WO2004112717A3 (en) | Conjugate for the specific targeting of anticancer agents to cancer cells and production thereof | |
| NZ309171A (en) | use of apoptin as an antitumour agent which specifically kills tumour and not normal cells | |
| AU7729498A (en) | Methods and uses for transposon-based gene targeting | |
| IL148360A0 (en) | A herpes viral mutant and pharmaceutical compositions containing the same | |
| WO2001064912A3 (en) | Triazine degrading enzymes | |
| GB0011060D0 (en) | Improvements relating to gene directed enzyme prodrug therapy | |
| WO2000067697A3 (fr) | Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules | |
| GB2379446A (en) | Cells,culture methods and their uses | |
| AR011100A1 (es) | Adn obtenible de s. clavuligerus, vector que comprende dicho adn, organismo hospedador, s. clavuligerus, procedimiento para mejorar la produccion de5r-clavam en un microorganismo adecuado, microorganismo que tiene las facultades para la produccion de 5r-clavam y una produccion baja o nula de 5s- | |
| AU5515501A (en) | Mammalian cell culture chamber | |
| WO2000066752A3 (en) | Gene construct for prodrug activation encoding a heterologous, glycosylphophati dylinositol-modified carboypeptidase g2 and a cell surface targettng signal peptide | |
| AU2002224102A1 (en) | Promoter for the culture of autrotrophic bacterium at high density | |
| CA2301874A1 (en) | Suppression of malignancy utilizing ribonucleotide reductase r1 |